Benjamin Weide
YOU?
Author Swipe
View article: Correlation of Baseline Tumor Burden with Clinical Outcome in Melanoma Patients Treated with Ipilimumab
Correlation of Baseline Tumor Burden with Clinical Outcome in Melanoma Patients Treated with Ipilimumab Open
Introduction: Tumor burden is a frequently mentioned parameter; however, a commonly accepted definition is still lacking. Methods: In this double-center prospective and retrospective study, 76 patients with unresectable stage III or stage …
View article: Supplementary Table 2 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Supplementary Table 2 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses Open
XLSX file - 82K, Change in frequency of cytokine-releasing T cells at different time points.
View article: Supplementary Table Legends from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Supplementary Table Legends from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma Open
PDF file 73K, This file contains legends for the five supplementary tables
View article: Supplementary Table S5 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Supplementary Table S5 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma Open
XLSX file 13K, Supplementary Table S5. PI3K pathway alterations. This table provides additional details on the PI3K pathway alterations observed in this cohort. Additional information regarding the time point, protein change, and appropria…
View article: Supplementary Table S4 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Supplementary Table S4 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma Open
PDF file, 12065K, Supplementary Table S4. Complete listing of all somatic mutations seen in all tumors. This table provides details on every non-synonymous mutation or short insertion/deletion observed in this cohort, with data on genomic …
View article: Data from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Data from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma Open
Most patients with BRAFV600-mutant metastatic melanoma develop resistance to selective RAF kinase inhibitors. The spectrum of clinical genetic resistance mechanisms to RAF inhibitors and options for salvage therapy are incompletely underst…
View article: Supplementary Table S5 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Supplementary Table S5 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma Open
XLSX file 13K, Supplementary Table S5. PI3K pathway alterations. This table provides additional details on the PI3K pathway alterations observed in this cohort. Additional information regarding the time point, protein change, and appropria…
View article: Supplementary Table S3 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Supplementary Table S3 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma Open
XLSX file 261K, Supplementary Table S3. Mutations seen in patients with tumors at one time point. For patients with whole exome sequencing data on either pre-treatment (for early resistance cases) or after relapse (for acquired resistance …
View article: Supplementary Methods from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Supplementary Methods from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses Open
PDF file - 81K, Detailed clinical course of disease in representative patients.
View article: Supplementary Table 2 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Supplementary Table 2 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses Open
XLSX file - 82K, Change in frequency of cytokine-releasing T cells at different time points.
View article: Supplementary Table 1 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Supplementary Table 1 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses Open
PDF file - 119K, List of lesions present at screening and overall patient responses (modified irRC and RECIST).
View article: Supplementary Methods from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Supplementary Methods from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses Open
PDF file - 81K, Detailed clinical course of disease in representative patients.
View article: Supplementary Figure 2 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Supplementary Figure 2 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses Open
PDF file - 870K, Detailed gating strategy of all the analyzed immune cell subsets.
View article: Supplementary Table Legends from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Supplementary Table Legends from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma Open
PDF file 73K, This file contains legends for the five supplementary tables
View article: Data from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Data from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses Open
L19–IL2 is a recombinant protein comprising the cytokine IL2 fused to the single-chain monoclonal antibody L19. In previous studies, intralesional injection with IL2 has shown efficacy for the locoregional treatment of cutaneous/subcutaneo…
View article: Supplementary Table S1 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Supplementary Table S1 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma Open
XLSX file 51K, Supplementary Table S1. Patient characteristics. Clinical characteristics for each patient are listed in this table, along with mean target coverage data for germline, pre-treatment, and resistant tumors (if available)
View article: Supplementary Table S2 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Supplementary Table S2 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma Open
XLSX file 327K, Supplementary Table S2. Mutations seen exclusively in resistant tumors. For patients with whole exome sequencing data on both pre-treatment and resistant tumors (n = 32), this table summarizes the complete set of non-synony…
View article: Supplementary Table S4 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Supplementary Table S4 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma Open
PDF file, 12065K, Supplementary Table S4. Complete listing of all somatic mutations seen in all tumors. This table provides details on every non-synonymous mutation or short insertion/deletion observed in this cohort, with data on genomic …
View article: Supplementary Table 1 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Supplementary Table 1 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses Open
PDF file - 119K, List of lesions present at screening and overall patient responses (modified irRC and RECIST).
View article: Supplementary Table S3 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Supplementary Table S3 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma Open
XLSX file 261K, Supplementary Table S3. Mutations seen in patients with tumors at one time point. For patients with whole exome sequencing data on either pre-treatment (for early resistance cases) or after relapse (for acquired resistance …
View article: Supplementary Table S1 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Supplementary Table S1 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma Open
XLSX file 51K, Supplementary Table S1. Patient characteristics. Clinical characteristics for each patient are listed in this table, along with mean target coverage data for germline, pre-treatment, and resistant tumors (if available)
View article: Supplementary Figure 1 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Supplementary Figure 1 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses Open
PDF file - 945K, Frequency and severity of common adverse events.
View article: Supplementary Figure 1 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Supplementary Figure 1 from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses Open
PDF file - 945K, Frequency and severity of common adverse events.
View article: Supplementary Table S2 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Supplementary Table S2 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma Open
XLSX file 327K, Supplementary Table S2. Mutations seen exclusively in resistant tumors. For patients with whole exome sequencing data on both pre-treatment and resistant tumors (n = 32), this table summarizes the complete set of non-synony…
View article: Data from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Data from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma Open
Most patients with BRAFV600-mutant metastatic melanoma develop resistance to selective RAF kinase inhibitors. The spectrum of clinical genetic resistance mechanisms to RAF inhibitors and options for salvage therapy are incompletely underst…
View article: Supplementary Figure 1 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Supplementary Figure 1 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab Open
Overall survival (OS) according to the combination model in the combined discovery/confirmation cohort and the validation cohort. Four baseline factors had independent prognostic impact (LDH, pattern of distant metastases, relative lymphoc…
View article: Supplementary Table 2 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Supplementary Table 2 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab Open
Overview of factors, cut-offs, and analysis of overall survival according to cohorts
View article: Supplementary Methods, Figures 1-4, Tables 1 from A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma
Supplementary Methods, Figures 1-4, Tables 1 from A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma Open
PDF file - 667K
View article: Supplementary Figure 3 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Supplementary Figure 3 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab Open
Overall survival according to the relative lymphocyte and eosinophil counts in 3 subgroups of patients defined by LDH and the pattern of visceral metastasis. Kaplan Meier curves for OS are presented according to relative lymphocyte count (…